A randomized, double-blind, Phase 3 study of standard chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of microsatellite-stable metastatic colorectal cancer.
Principal Investigator
Dott.ssa Elisabetta Fenocchio
Contact Information for Access
Phase
FASE III
Status
IN ATTIVAZIONE
Objective of the study
The objective of the study is to confirm that treatment with bevacizumab and INCA33890 is clinically superior to chemotherapy with bevacizumab alone.
Pathologies
Gastrointestinal tumor (GI tumor)
Medication
bevacizumab with or without INCA33890
Who is eligible to participate in the study?
Patients who are 18 years of age or older and who meet the study’s eligibility criteria may participate in this study.
Patients who have not received prior treatment.
View the full study Back to search page